Gsa Capital Partners LLP Adc Therapeutics Sa Transaction History

Gsa Capital Partners LLP

  • $1.35 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023
BUY
$0.72 - $2.37 $9,368 - $30,838
13,012 Added 11.95%
121,897 $109,000
Q2 2023

Aug 14, 2023
BUY
$1.9 - $2.66 $161,950 - $226,730
85,237 Added 360.44%
108,885 $234,000
Q1 2023

May 12, 2023
BUY
$1.92 - $5.45 $45,404 - $128,881
23,648 New
23,648 $46,000

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
53.5M
Call Options Held
28K
Put Options Held
60.4K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $124M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email